Focus:
Analysis
-
![National Heart Month: how can you heal a broken heart?]()
National Heart Month: how can you heal a broken heart?
February is National Heart Month in the US and the US, which focuses on raising awareness of heart disease. Often caused by emotional distress, takotsubo cardiomyopathy is a rare heart...
-
![Pharmaceutical packaging in 2019: the view from Origin’s Rich Quelch]()
Pharmaceutical packaging in 2019: the view from Origin’s Rich Quelch
The pharmaceutical packaging market is always challenging and 2019 will be no exception. What will rising demand from emerging economies, ageing demographics, new technologies and drug discoveries mean for pharmaceutical...
-
![antiSMASH: on the hunt for new antibiotics]()
antiSMASH: on the hunt for new antibiotics
Online tool antiSMASH is being used by scientists on the hunt for interesting bacterial metabolites with potential uses for creating new antibiotics, and its accompanying database was recently updated to...
-
![The Petri dish: telling the story of pharma’s most humble ally]()
The Petri dish: telling the story of pharma’s most humble ally
Well known to anyone familiar with a science classroom, the Petri dish has been used in medicine for well over a hundred years. Has it changed? Yes and no, but...
-
![Tackling consequences of air pollution with drug R&D]()
Tackling consequences of air pollution with drug R&D
Air pollution is a leading cause of death globally, as well as being responsible for new cases of chronic respiratory illnesses, such as asthma and COPD, and lung cancer, it...
-
![World Cancer Day 2019: three promising therapies for neglected rare cancers]()
World Cancer Day 2019: three promising therapies for neglected rare cancers
World Cancer Day was established in 2000. Oncology accounts for a large proportion of global pharma R&D spending, but rare cancers, which make up 20% of all cancer cases collectively,...
-
![Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus]()
Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
In this issue: Knock on effects of the Valsartan recall, the future of AI in healthcare, the history of the Petri dish, and much more.
-
![Developing a new class of cancer combo drugs]()
Developing a new class of cancer combo drugs
Cybrexa, a spin-out company from Yale University, is developing a new class of cancer therapeutics, looking to identify combinations of chemotherapy and DNA inhibitors to increase efficacy and reduce toxicity...
-
![Not so elementary, Watson: the roadblocks for AI in pharma]()
Not so elementary, Watson: the roadblocks for AI in pharma
The high-profile flaws shown by IBM’s Watson for Oncology this year has dented the reputation of AI-driven systems for healthcare and pharma R&D. So what are the roadblocks standing in...
-
![Data overload: turning challenges into opportunities in clinical trials]()
Data overload: turning challenges into opportunities in clinical trials
Clinical research is creating more data than ever before, but are we making the most of it or are we at risk of getting overwhelmed by the sheer amount of...
